BTIG analyst Julian Harrison upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Aclaris (ACRS) stock rallied 53% Monday after the company announced it had exclusively licensed two drug candidates from Biosion, prompting an upgrade by Piper Sandler.

This compound comes in both form and gel form and garnered its first FDA approval in 2022. Zoryve is now approved to treat ...

CRANBURY, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MJH Life Sciences ®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic ...